Adjuvant Palbociclib in Elderly Patients With Breast Cancer
Status:
Recruiting
Trial end date:
2032-06-13
Target enrollment:
Participant gender:
Summary
Phase II study to assess the efficacy of the combination of at least 5 year endocrine therapy
and 2 year-palbociclib as adjuvant systemic treatment instead of adjuvant chemotherapy
followed by endocrine therapy in older patients with stage II-III ER+/HER2- early breast
cancer.
Phase:
Phase 2
Details
Lead Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC
Collaborators:
German Adjuvant Breast Cancer Group Gruppo Oncologico Italiano di Ricerca Clinica International Breast Cancer Study Group Pfizer SOLTI Breast Cancer Research Group Swedish Association of Breast Oncologists UNICANCER